Critères d'inclusion : ATTENTION LISTE NON EXHAUSTIVE
- Histologically-confirmed transitional cell carcinoma of the urothelium of the upper or lower urinary tract
- Recurrent or progressing stage IV disease, or surgically unresectable, recurrent or progressing disease
- Documented central FGFR genetic alteration
- Measurable disease per RECIST 1.1
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2
- Adequate bone marrow, liver and renal function
Critères de non-inclusion : ATTENTION LISTE NON EXHAUSTIVE
- Receipt of chemotherapy, targeted therapies, immunotherapy, or treatment with an investigational anticancer agent within 2 weeks or at least 5 half-lives of the drug whichever is longer before the first dose of study drug.
- Concurrent evidence of any clinically significant corneal or retinal disorder
- Phosphatemia greater than institutional upper limit of normal (ULN) at screening
- Uncontrolled tumor-related hypercalcemia